This was a nationwide population-based cohort study from South Korea using health insurance data linked with environmental monitoring records. It included over 36,000 women with uterine cancer and more than 144,000 matched women without cancer, followed from 2008 to 2019. Researchers estimated exposure to different THMs (by municipality water measurements) and examined whether higher exposure was associated with new cases of uterine and cervical cancer. The main outcomes were incidence of uterine (endometrial) and cervical cancers, analyzed across quartiles of THM exposure using statistical models adjusted for multiple confounders.
Women living in areas with the highest levels of total trihalomethanes and chloroform in drinking water had a statistically significant higher risk of developing uterine (endometrial) cancer compared with those in the lowest exposure group (adjusted hazard ratios modestly above 1). The association followed a dose–response pattern: as THM and chloroform levels increased across quartiles, uterine cancer risk increased. Associations with cervical cancer were weaker or not consistently significant, suggesting the effect may be more specific to endometrial tissue. The observed effect sizes were small to moderate, indicating that THMs are likely one contributing factor among many rather than a dominant cause.
Exposure was estimated at the community level based on municipal water monitoring, not on individual water intake, filtration, or bottled water use, which can lead to misclassification. As an observational study, it cannot prove cause and effect; women in higher-THM areas might differ in other unmeasured ways (socioeconomic status, diet, urbanization, other pollutants) that also affect cancer risk. The population was entirely Korean, so results may not generalize directly to other countries with different water treatment methods, genetic backgrounds, or lifestyle patterns. THM levels in this study may differ from those in North America or Europe, and the paper does not address combined effects with other chemicals; more mechanistic and prospective studies are needed before making strong policy or clinical recommendations.
This study is methodologically strong in scale and design, using a large, nationwide database with linkage to standardized water-quality monitoring, along with matching and multivariable adjustment. However, exposure is ecological (area-level) rather than individual, and unmeasured confounding (e.g., diet, detailed reproductive history, endocrine-disrupting exposures) remains a concern. The findings align with broader evidence that chlorination byproducts and other environmental contaminants may influence hormone-sensitive cancers, but the literature is still limited and not entirely consistent, especially outside East Asian populations. Clinically, the results support including environmental toxicant exposure in a comprehensive, root-cause evaluation for uterine pathology, while recognizing that individual absolute risk from THMs alone remains relatively low and the evidence is observational.
For patients, this adds to the motivation to pay attention to water quality, especially if living in areas with known water-quality issues or heavy chlorination; home filtration certified to reduce chlorination byproducts may be considered. For restorative care, environmental history-taking (water source, home filtration, workplace exposures) can be integrated alongside assessment of cycle patterns, hormonal balance, metabolic health, and inflammation. Lifestyle strategies that support detoxification pathways—adequate hydration, fiber, sleep, and avoiding additional unnecessary chemical exposures (e.g., tobacco, excess alcohol, some solvents)—remain reasonable, low-risk measures. Any abnormal uterine bleeding, especially after age 35–40 or after menopause, should still trigger prompt gynecologic evaluation regardless of water exposure history.
This study looked at whether certain chemicals formed when water is disinfected (trihalomethanes) might be linked to a higher chance of uterine cancer. Women who lived in places with more of these chemicals in tap water had a higher rate of uterine (endometrial) cancer, but the increase in risk was modest and does not mean that every individual with this exposure will get cancer. For someone on a fertility journey, this highlights that environmental factors—like water and chemical exposures—can be part of the root-cause picture along with hormones, weight, blood sugar, inflammation, and cycle irregularities. It’s reasonable to be mindful of water quality and other avoidable toxins, but the most important step is working with your clinician to evaluate abnormal bleeding, painful or very heavy periods, and cycle changes early so issues can be caught and supported sooner.
Consider incorporating structured environmental exposure screening into reproductive and uterine-health evaluations: drinking-water source, use/type of filtration, workplace chemical exposure, and residential history in high-chlorination or industrial areas. This study suggests that chronic low-level exposure to THMs, especially chloroform, may modestly increase endometrial cancer risk, fitting with a broader endocrine-disruptor narrative; however, absolute risks remain small and the data are observational. Within a restorative framework, continue to prioritize modifiable high-impact drivers—obesity, insulin resistance, anovulation, unopposed estrogen, chronic inflammation—while counseling about environmental stewardship (e.g., NSF-certified carbon filtration for patients at higher overall risk or with significant exposure concerns). For patients with abnormal uterine bleeding or endometrial hyperplasia, note environmental exposures in the chart, but do not let this delay standard diagnostic workup (TVUS, endometrial sampling when indicated, metabolic and hormonal profiling); consider following biomarkers related to oxidative stress and metabolic health where appropriate, while acknowledging that specific THM biomarkers are not yet part of routine clinical practice.
Educational insights, not a diagnosis or individualized treatment advice. Discuss findings with your own clinician. Visit Reproductive Health Insights to explore fertility resources.